Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions: Results from a nested case-control study in northern Sweden

Stroke

Volumn 30, Issue 10, 1999, Pages 2013-2018

  Glader, Christine Ahlbeck ^a   Stegmayr, Birgitta ^b   Boman, Jens ^b   Stenlund, Hans ^b   Weinehall, Lars ^b   Hallmans, Göran ^b   Dahlén, Gösta H ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b NONE

Author keywords

Chlamydia pneumoniae; Ischemic cerebrovascular disease; Lipoprotein(a)

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPROTEIN A;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CASE CONTROL STUDY; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SWEDEN;

EID: 0032824645     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.10.2013     Document Type: Article

References (55)

1. Dahlén GH, Ericson C, Furberg C, Lundkvist L, Svärdsudd K. Studies on an extra pre-beta lipoprotein fraction. Acta Med Scand Suppl. 1972; 531:1-29.
2. Dahlén GH. Lipoprotein (a) as a risk factor for atherosclerotic diseases. Arctic Med Res. 1988;47(suppl 1):458-461.
3. Rhoads GG, Dahlén GH, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256: 2540-2544.
4. Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM J. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
5. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Quinici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51-61.
6. Zenker G, Költringer P, Boné G, Niederkorn K, Pfeiffer K, Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17:942-945.
7. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
8. Nagayama M, Shinohara Y, Nagayama T. Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke. 1994;25:74-78.
9. Pedro-Botet J, Sentí M, Nogués X, Rubiés-Prat J, Roquer J, D'Olhaberriague L, Olivé J. Lipoprotein and apolipoprotein profile in men with ischemic stroke: role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke. 1992;23: 1556-1562.
10. Jürgens G, Költringer P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology. 1987;37:513-515.
11. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke. 1993;24:965-969.
12. Woo J, Lau E, Lam CW, Kay R, Teoh R, Wong HY, Prall WY, Kreel L, Nicholls MG. Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke. 1991;22:203-208.
13. Schreiner PJ, Chambless LE, Brown SA, Watson RL, Toole J, Heiss G. Lipoprotein(a) as a correlate of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC Study: Atherosclerosis Risk in Communities. Ann Epidemiol. 1994;4:351-359.
14. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA. 1995;273:1269-1273.
15. Bova IY, Bornstein NM. Korczyn AD. Acute infection as a risk factor for ischemic stroke. Stroke. 1996;27:2204-2206.
16. Ameriso SF, Wong VLY, Quismorio FP Jr, Fisher M. Immunohematologic characteristics of infection-associated cerebral infarction. Stroke. 1991;22:1004-1009.
17. Syrjänen J, Valtonen VV, livanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br Med J [Clin Res Ed]. 1988;296: 1156-1160.
18. Saikku P, Leinonen M, Manila K, Ekman MR, Nieminen MS, Mäkelä PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-986.
19. Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, Manttari M, Frick MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273-278.
20. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 1992;82:158-161.
21. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841-849.
22. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A. 1995;92:6911-6914.
23. Dahlén GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis. 1995;114: 165-174.
24. Söderberg S, Ahrén B, Stegmayr B, Johnson O, Wiklund PG, Weinehall L, Hallmans G, Olsson T. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke. 1999;30:328-337.
25. Weinehall, L. Partnership for Health: On the Role of Primary Health Care in a Community Intervention Programme [PhD thesis]. Umeå, Sweden: Umeå University; 1997.
26. Tunstall-Pedoe H. The World Health Organization MONICA Project (Monitoring of Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol. 1988;41:105-114.
27. Stegmayr B, Asplund K. Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. Neuroepidemiology. 1992;11:204-213.
28. Wimmer MLJ, Sandmann SR, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. Stroke. 1996;27: 2207-2210.
29. Cook PJ, Honeybourne D, Lip GYH, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke. 1998;29:404-410.
30. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Stroke. 1999;30: 299-305.
31. Karvonen M, Tuomilehto J, Pitkäniemi J, Naukkarinen A, Saikku P. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol. 1994;23:1315-1321.
32. Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, Wang SP. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990;161:618-625.
33. Boman J, Allard A, Persson K, Lundborg M, Juto P, Wadell G. Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA. J Infect Dis. 1997;175:1523-1526.
34. Campbell LA, O'Brien ER, Cappuccio AL, Kuo CC, Wang SP, Stewart D, Patton DL, Cummings PK, Grayston JT. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis. 1995;172:585-588.
35. Puolakkainen M, Kuo CC, Shor A, Wang SP, Grayston JT, Campbell LA. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol. 1993;31:2212-2214.
36. Jovicic A, Ivanisevic V, Ivanovic I. Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis. 1993;98:59-65.
37. Markus HS, Kapadia R, Sherwood RA. Relationship between lipoprotein (a) and both stroke and carotid atheroma. Ann Clin Biochem. 1997;34:360-365.
38. Min WK, Lee JO, Huh JW. Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease. Clin Chem. 1997;43:1891-1895.
39. Noma A, Abe A, Maeda S, Seishima M, Makino K, Yano Y, Shimokawa K. Lp(a): an acute-phase reactant? Chem Phys Lipids. 1994;67/68:411-417.
40. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145-150.
41. Kawade M, Maeda S, Abe A, Yamashiro M. Alterations in plasma Lp(a) lipoprotein and acute phase proteins after surgical operation. Clin Chem. 1984;30:941. Abstract.
42. Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY. The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta. 1993;223:73-82.
43. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke. 1988;19:937-941.
44. Kannel WB, Hjortland MC. McNamara PM, Gordon T. Menopause and risk of cardiovascular disease. Ann Intern Med. 1976;85:447-452.
45. Meilahn EN, Kuller LH, Matthews KA, Stein EA. Lp(a) concentrations among pre-and postmenopausal women over time: the Healthy Women Study. Circulation. 1991;84(suppl II):II-546. Abstract.
46. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb. 1994;14:275-281.
47. Mijatovic V, Kenemans P, Netelenbos JC, Peters-Muller ERA, van Kamp GJ, Voetberg GA, van de Weijer PH, van der Mooren MJ. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women. J Clin Endocrinol Metab. 1997;82:3543-3547.
48. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
49. Dahlén GH. Indications of an autoimmune component in Lp(a) associated disorders. Eur J Immunogenet. 1994;21:301-312.
50. Young CL, Baker WC, Tomaselli CM, Dayhoff MO. Serine proteases. In: Dayhoff MO, ed. Atlas of Protein Sequence and Structure. Silver Spring, Md: National Biomedical Research Foundation; 1978;5:3:73.
51. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog. 1996;21:215-221.
52. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13:1501-1504.
53. Gianturco SH, Bradley WA, Dahlén GH, Ganbatz JW, Giotto AM Jr. Morrisett JD, Peavy DL. Interaction of lipoprotein(a) with murine peritoneal macrophages and cultured human fibroblasts. Arteriosclerosis. 1983;3:500a. Abstract.
54. Dahlén GH, Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet. 1997;52:272-280.
55. Boman J, Söderberg S, Forsberg J, Birgander LS, Allard A, Persson K, Jidell E, Kumlin U, Juto P, Waldenström A, Wadell G. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis. 1998;178:274-277.